Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
VNDA
VNDA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VNDA News
Wall Street Analysts Adjust Ratings
5d ago
Benzinga
FDA Grants Hearing for Vanda's Hetlioz Jet Lag Drug
6d ago
seekingalpha
FDA Grants Vanda Hearing on Jet Lag Drug Rejection
6d ago
stocktwits
FDA Grants Vanda Hearing on HETLIOZ® Jet Lag Application
Mar 03 2026
PRnewswire
FDA Grants Vanda Hearing on HETLIOZ® Jet Lag Application
Mar 03 2026
Newsfilter
Vanda Pharmaceuticals to Participate in 2026 Citizens Life Sciences Conference
Feb 26 2026
PRnewswire
Vanda Pharmaceuticals to Participate in 2026 Citizens Life Sciences Conference
Feb 26 2026
Newsfilter
Vanda Pharmaceuticals' New Drug Approved by FDA
Feb 25 2026
Benzinga
Vanda Pharmaceuticals Seeks FDA Approval for Imsidolimab
Feb 25 2026
stocktwits
Vanda Pharmaceuticals Files BLA for Imsidolimab to Treat GPP
Feb 25 2026
PRnewswire
Vanda Pharmaceuticals Files BLA for Imsidolimab to Treat GPP
Feb 25 2026
Newsfilter
FDA Approval of Bysanti Enhances Vanda's Portfolio
Feb 24 2026
Benzinga
Vanda Pharmaceuticals' Bysanti Receives FDA Approval
Feb 23 2026
Benzinga
Stock Futures Dip as Vanda Pharma Gains on FDA Approval
Feb 23 2026
seekingalpha
U.S. Stock Futures Decline Following Supreme Court Tariff Ruling
Feb 23 2026
Benzinga
Vanda Pharmaceuticals Shares Surge 33% in Pre-Market Trading
Feb 23 2026
Benzinga
Show More News
